International Journal of Drug Delivery Technology
Volume 14, Issue 1

Pharmacological Approaches in Rheumatoid Arthritis- An In-depth Analysis of Prescribed Medications

James E, Suseem SR*

Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore, Tamil Nadu, India 

Received: 15th December, 2023; Revised: 25th January, 2024; Accepted: 18th February, 2024; Available Online: 25th March, 2024

ABSTRACT

Inflammation, pain, swelling, and stability of the joints are some of the symptoms associated with rheumatoid arthritis (RA). A variety of treatment options are available to manage symptoms and slow the progression of RA, despite the fact that there is no cure. This cross-sectional study, which was conducted in a tertiary care hospital in Kerala, India, aimed to evaluate medication prescribing practices and therapeutic strategies in RA patients. The study included 280 RA patients and data on demographics, medications prescribed, dosage, and mode of administration were collected. The findings revealed that disease-modifying anti- rheumatic drugs (DMARDs) were the cornerstone of RA treatment, with hydroxychloroquine (HCQ), methotrexate (MTX), and sulfasalazine (SAAZ) being the most frequently prescribed DMARDs. Combination DMARD therapy, particularly the triple combination of HCQ + Folitrax + SAAZ, was prevalent among patients. Furthermore, the study highlighted the use of biologic DMARDs, such as rituximab and tofacitinib, albeit at a relatively lower rate due to the outpatient population’s milder disease severity. Supplement therapy, including vitamin D3 and folic acid, was commonly prescribed to address deficiencies and mitigate the side effects of medications like MTX. The prescription patterns also encompassed analgesics, anti-anxiety, and antidepressant medications to manage pain and psychological symptoms associated with RA. Steroids were administered initially to control inflammation, with a focus on minimizing long-term usage. The study underscores the complexity of RA management and the importance of individualized treatment approaches. It highlights the evolving landscape of RA therapeutics, emphasizing the need for clinicians to stay updated on emerging evidence and guidelines. Future research should focus on evaluating the long-term efficacy, safety, and cost-effectiveness of different treatment regimens to optimize patient outcomes in RA management.

Keywords: Rheumatoid arthritis, Medication usage, DMARDs, Combination therapy, Biologics, Therapeutic strategies, Indian population.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.1.30

How to cite this article: James E, Suseem SR. Pharmacological Approaches in Rheumatoid Arthritis- An In-depth Analysis of Prescribed Medications. International Journal of Drug Delivery Technology. 2024;14(1):203-209.

REFERENCES

  1. Nair SC, et al. Medication prescribing practices in rheumatoid arthritis management: A tertiary care hospital study in Kerala, India. Indian J Rheumatol. 2016;11(2):82-87.
  2. Feng X, et al. The role of vitamin D in the pathogenesis and t reatment of rheumatoid Rheumatol Int. 2013;33(8):1939-1950.
  3. Bello AE, et al. Comparative effectiveness and safety of tofacitinib, etanercept and adalimumab in RA: a mixed treatment Ann Rheum Dis. 2017;76(Suppl 2):735.
  4. Kavanaugh Treatment of rheumatoid arthritis with biological agents. Rheumatology (Oxford). 2006;45(Suppl 3):iii17-iii21.
  5. Jebastine MI, et al. Pattern and predictors of remission in rheumatoid arthritis patients: A prospective cohort Indian J Rheumatol. 2015;10(1):4-9.
  6. Dutta SB, et al. Efficacy and safety of rituximab in rheumatoid arthritis patients with an inadequate response to conventional disease-modifying anti-rheumatic drugs: a meta-analysis of randomized controlled Rheumatol Int. 2017;37(6):907-915.
  7. Dahiya A, et al. Efficacy and safety of biological agents in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials. Rheumatol Ther. 2016;3(2):209-228.
  8. Syngle A, et al. Prevalence and predictors of comorbid fibromyalgia syndrome in patients with rheumatoid arthritis: A cross-sectional study. Rheumatol Int. 2017;37(5):751-759.
  9. Rai AK, et al. Effect of hydroxychloroquine on cardiovascular events and mortality in rheumatoid arthritis patients: A systematic review and meta-analysis of randomized controlled trials. Rheumatol Int. 2016;36(3):417-425.
  10. Kostoglou-Athanassiou I, et al. Vitamin D supplementation in rheumatoid arthritis patients: A systematic review and meta- analysis of randomized controlled trials. Rheumatol Ther. 2018;5(1):25-45.
  11. Heidari B, et al. Efficacy and safety of tocilizumab in rheumatoid arthritis patients with inadequate response to conventional disease-modifying anti-rheumatic drugs: A meta-analysis of randomized controlled trials. Rheumatol Int. 2019;39(7):1179-
  12. Buttgereit F, et al. Long-term low-dose glucocorticoid therapy in rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled Rheumatology. 2018;57(5):968-978.